<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04925167</url>
  </required_header>
  <id_info>
    <org_study_id>Argatroban in V-V ECMO</org_study_id>
    <nct_id>NCT04925167</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Argatroban Applicated in Anticoagulation of V-V ECMO</brief_title>
  <official_title>Safety and Efficacy of Argatroban Applicated in Anticoagulation of V-V ECMO: A Randomized Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Chao Yang Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Chao Yang Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Unfractionated heparin is most common in the anticoagulation management of V-V ECMO. However,&#xD;
      many side effects of unfractionated heparin, such as HIT, antithrombin deficiency, etc&#xD;
      seriously affects the prognosis of patients. Argatroban is kind of direct thrombin&#xD;
      inhibitors, which could be used used as an alternative anticoagulant of unfractionated&#xD;
      heparin when HIT or antithrombin deficiency, etc. At present, there is no power enough&#xD;
      evidence for the application of argatroban in V-V ECMO. This study aims to evaluat the safety&#xD;
      and effectiveness of argatroban in the anticoagulation management of V-V ECMO compared with&#xD;
      unfractionated heparin.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 6, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>incidence of ECMO related thrombotic events</measure>
    <time_frame>14 days</time_frame>
    <description>the incidence of ECMO related thrombotic events, such as membrane oxygenator or tube thrombosis.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">174</enrollment>
  <condition>Respiratory Failure</condition>
  <arm_group>
    <arm_group_label>argatroban group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients received argatroban for anticoagulation during V-V ECMO.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>UFH group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients received UFH for anticoagulation during V-V ECMO.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Argatroban</intervention_name>
    <description>Argatroban continuous intravenous injection maintained APTT at 1.5 times of baseline.</description>
    <arm_group_label>argatroban group</arm_group_label>
    <other_name>Novastan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>unfractionated heparin</intervention_name>
    <description>unfractionated heparin continuous intravenous injection maintained APTT at 1.5 times of baseline.</description>
    <arm_group_label>UFH group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  age older than 18 years old; received V-V ECMO because of sevever respiratory failure&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  anticoagulant contraindications; Confirmed or suspected, or previously diagnosed with&#xD;
             heparin induced thrombocytopenia; Cerebral infarction or suspected patients; Patients&#xD;
             with severe liver dysfunction; Allergic to heparin or argatroban; hemophilia;&#xD;
             Unwilling or unable to complete the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bing Sun, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Chao Yang Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bing Sun, MD</last_name>
    <phone>+8613911151075</phone>
    <email>ricusunbing@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Bing Sun</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100020</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bing Sun, MD</last_name>
      <phone>+8613911151075</phone>
      <email>ricusunbing@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>June 11, 2021</study_first_submitted>
  <study_first_submitted_qc>June 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 14, 2021</study_first_posted>
  <last_update_submitted>July 6, 2021</last_update_submitted>
  <last_update_submitted_qc>July 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Chao Yang Hospital</investigator_affiliation>
    <investigator_full_name>Bing Sun</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Insufficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heparin</mesh_term>
    <mesh_term>Calcium heparin</mesh_term>
    <mesh_term>Argatroban</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Study protocal, statistical analysis plan, informed consent form and clinical study report will be shared.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>1 year after the study completed.</ipd_time_frame>
    <ipd_access_criteria>Contact PI by email with reasonable reasons.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

